Blinktbi
EyeStat: World's first FDA-cleared device for quick, objective blink reflex assessment.
Founded
2017EyeStat: World's first FDA-cleared device for quick, objective blink reflex assessment.
Blinktbi, founded with a vision to revolutionize medical diagnostics, focuses on developing innovative medical devices. Their flagship product, EyeStat, is the world's first FDA-cleared device designed for the rapid and objective assessment of the blink reflex. This technology aims to provide immediate and quantitative data, particularly useful for identifying abnormal blink patterns associated with traumatic brain injuries. Blinktbi targets healthcare providers and sports organizations, emphasizing the importance of quick and accurate diagnostics in medical and athletic settings.
Notable affiliations include collaborations with clinical experts and research institutions to validate and expand the applications of their technology. EyeStat's FDA clearance marks a significant achievement, underscoring its reliability and potential impact on medical diagnostics. By providing a swift and objective method to assess blink reflexes, Blinktbi has made a substantial contribution to the early detection and management of traumatic brain injuries, enhancing patient care and safety in high-risk environments like sports.
Companies similar to Blinktbi include Oculogica, Rebion, Blink Technologies and NeuroChaos Solutions.
Blinktbi was founded in 2017.
Blinktbi's headquarters is located in Charleston, SC, US.
Blinktbi's most recent funding round was for $6M (USD) in January 2020.
As of Jan 15, 2020, Blinktbi has disclosed funding of $7.6M (USD). Undisclosed round amounts are excluded.
Blinktbi has 35 employees as of Feb 5, 2024.
neurochaos.com
